Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Advanced Merger Partners (AMPI.U)
Anzu Special Acquisition I (ANZU.U)
Nightdragon Acquisition (NDACU)
Supernova Partners Acquisition II (SNII.U)
Dhb Capital (DHBCU)
Orion Acquisition Corp. (OHPAU)
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Live Oak Mobility Acquisition (LOKM.U)
Property Solutions Acquisition II (PSAGU)
Atlantic Coastal Acquisition (ACAHU)
Khosla Ventures Acquisition Co. (KVSA)
TCW Special Purpose Acquisition Corp. (TSPQ.U)
Aurora Acquisition Corp. (AURCU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Roblox Corporation (RBLX)
Coupang, Inc. (CPNG)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Sana Biotechnology, Inc. (SANA)

Sector - Healthcare

Price chart

+32.8%
Return from IPO

Company News

IPO Profile

About company

They were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. They view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Their long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines. They have brought together an experienced group of scientists, engineers, and company builders and combined them with the necessary technologies to move this vision forward. They are developing in vivo and ex vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. While their current product candidates are all in preclinical development, their goal is to file multiple investigational new drug applications (INDs) both in 2022 and 2023.
Industry
Pharmaceuticals
CEO CFO
Steven D. Harr Nathan Hardy
Employees Founded
2018

Contacts

Address: 188 East Blaine Street, Suite 400 Seattle, Washington 98102

Telephone: (206) 701-7914

Web page: http://www.asana.com

IPO information

Expected Date 2/4/2021
Status Priced
Exchange NYSE
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 15
Shares Revised (MM) 23.5
Expected offer amount (MM) $322.5
Realized offer amount(MM) $587.5

Financial Data (last reporting year)

Market Cap (MM) $3769.38
Revenues (MM) $0
Net Income (Loss) (MM) $-215.2

Voting

What do you think will happen with the SANA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ Goldman Sachs/ JP Morgan/ BofA Securities
CO-Managers
-

Sector: Healthcare

Tweets about $SANA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats